Skip to main content

Table 2 Chemoradiation (CRT) details and outcomes

From: Efficacy and feasibility of ambulatory treatment-based monthly nedaplatin plus S-1 in definitive or salvage concurrent chemoradiotherapy for early, advanced, and relapsed esophageal cancer

 

No.

%

Intent of CRT

  

 Definitive

67

75.3

 Salvage

22

24.7

Radiation total dose

  

 19.8Gy

1

1.1

 50Gy

9

10.1

 50.4Gy

57

64.1

 60Gy

22

24.7

NDP/TS-1 total cycles

  

 One

5

5.6

 Two

60

67.4

 Three

3

3.4

 Four

21

23.6

Hospitalization during CRT

  

 Median

2 days

 Range

0–50 days

Post-CRT morbidity

  

 Grade 5

1

1.1

 Grade 4

2

2.2

 Grade 3

4

4.5

State at censoring

  

 Alive without disease

49

55.1

 Alive with disease

13

14.6

 Dead of disease

13

14.6